Tianjin Lisheng Pharmaceutical002393.SZValuation Analysis

As of Oct 19, 2026, Tianjin Lisheng Pharmaceutical (002393.SZ) trades at a P/E of 27.80x, P/B of 0.94x, P/S of 3.29x, and a dividend yield of 5.47%.
Longitudinal percentile comparison: P/E sits at the 44th percentile over the trailing 10Y window (vs. 92nd percentile over 3Y); P/B sits at the 31st percentile over the trailing 10Y window (vs. 42nd percentile over 3Y); P/S sits at the 32nd percentile over the trailing 10Y window (vs. 18th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 37th percentile within its industry and the 39th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 8.35%, ranking at the 100th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 12.7 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 5.47% comes from cash dividends, with an implied ~2.87% from buybacks — a fairly balanced mix of both channels. Tianjin Lisheng Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.